CoreCap Advisors’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

CoreCap Advisors’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$5.39K	Buy	+266	New	+$4.08K	﹤0.01%	1729
2022 Q3	–	Sell	-266	Closed	-$3K	–	2308
2022 Q2	$3K	Buy	+266	New	+$4.29K	﹤0.01%	1825
2022 Q1	–	Sell	-266	Closed	-$9K	–	2302
2021 Q4	$9K	Buy	+266	New	+$7.41K	﹤0.01%	1605

Other funds holding OPNT

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

ACA

Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

NYLIM

New York Life Investment Management New York $11.8B AUM 23.45% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Ramius Advisors New York $95.2M AUM 7.33% 1-Year Est. Return

CoreCap Advisors's OPNT Position: Q4 2022 in Review

CoreCap Advisors opened a new position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q4 2022: 266 shares worth $5.39K. The stake represents ﹤0.01% of the portfolio and ranks #1729 among its holdings. This is a return to the name: CoreCap Advisors previously reported a position in OPNT as recently as Q2 2022.

CoreCap Advisors first reported a position in OPNT in Q4 2021 and has held it in 3 quarters since. The position peaked at $9K in Q4 2021. 37 funds tracked by Wall St. Rank hold OPNT as of Q4 2022.

CoreCap Advisors held 266 shares of Opiant Pharmaceuticals, Inc. Common Stock worth $5.39K as of Q4 2022.
Opiant Pharmaceuticals, Inc. Common Stock was a new CoreCap Advisors position in Q4 2022.
Opiant Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of CoreCap Advisors's portfolio in Q4 2022, its #1729 holding.
CoreCap Advisors first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q4 2021 and has held it in 3 quarters since.
CoreCap Advisors's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $9K in Q4 2021.
37 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on CoreCap Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.